<div class="chapter-header">
	<div class="white-sheet">
		
		<div class="title-bar red"></div>

		<div class="wrapper slide-3-1">

			<div class="nav">
				<button class="blue active arrow_box navigate" data-navtarget="mod_3_home">MODULE 3</button>

				<button class="blue arrow_box navigate" data-navtarget="slide_g_1_3">GLOSSARY</button>

				<button class="blue arrow_box navigate" data-navtarget="slide_sa_3">SELF-ASSESSMENT</button>
				
				<button class="blue arrow_box show-overlay" data-effect="fade" data-duration="1000" data-target="learning-objectives-overlay" data-width="600" data-height="490">LEARNING OBJECTIVES</button>

				
				<!-- <button class="prev-chap navigate" data-navtarget="slide_2_9_2"></button> -->
				<button class="next-chap navigate" data-navtarget="slide_3_1_1"></button>

			</div>

			<div class="chapter-title one-line">
				<div class="chapter-num">3.1</div>
				<div class="title-1">Eltrombopag: mode of action</div>
			</div>

			<button class="big-blue navigate" data-navtarget="slide_3_1_1">ENTER</button>

			<div class="learning-objectives-overlay overlay">

				<header>Learning Objectives</header>
			
				<ul>
					<li><span>By the end of this module you should be able to:</span>
						<ul>
							<li><span>Understand the details of the clinical trials and the outcomes relating to eltrombopag use in severe aplastic anaemia (SAA)</span>
								<ul>
									<li><span>Preclinical data in mice show that eltrombopag can stimulate multilineage haematopoiesis </span></li>
									<li><span>Phase II results demonstrate that eltrombopag can improve haematopoiesis in â‰¥1 cell lineage in patients with refractory aplastic anaemia</span>
										<ul>
											<li><span>A multilineage haematological response was observed in some patients, with an increase in platelet, red blood cell (RBC) and neutrophil levels after treatment with eltrombopag</span></li>
											<li><span>The number of cell lineages that met haematological response improved over time for some patients</span></li>
											<li><span>Response was maintained in patients whose treatment was tapered because of improvements in defined multilineage blood counts (platelets, erythrocytes and neutrophils)</span></li>
										</ul>
									</li>
								</ul>
							</li>
							<li><span>Appreciate that cytogenetic abnormalities and subsequent evolution to haematological malignancies are known long-term risks in patients with bone marrow disorders, particularly in patients with SAA</span>
								<ul>
									<li><span>Patients with aplastic anaemia are at risk for developing myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML)</span></li>
								</ul>
							</li>
						</ul>
					</li>
				</ul>

			</div>

		</div>

	</div>
</div>
